New Molecular Modalities
MEGA Webinar
New Molecular Entity Modalities are changing the drug discovery landscape. It is no longer small molecule and large molecule but more like 13 or more types of molecules that need new processes, informatics, molecular representation, and handling.
Examples of New Molecular Entity Modalities:
-
Antibody Drug Conjugate (ADC)
-
PROTACs
-
Small Molecules
-
Antibodies (Monoclonal , Bispecific, Fragment)
-
Peptide or Protein
-
Nucleotide Based
-
Cell Based
-
In Vivo Expressed Biologics (IVEBs)
We will explore these needs in detail with our sponsors and partners to show you how different companies are making a huge impact in this space!
Thank you to our top sponsor Revvity Signals (formerly PerkinElmer Informatics)!
Presentations
Pioneering New Modalities:
The Future of Therapeutic Leadership​​
​
In this webinar, we will explore the transformative potential of multimodal drug discovery in shaping the future of therapeutic leadership. As the pharmaceutical and biotechnology landscape rapidly evolves, embracing diverse strategies and harnessing the power of new modalities has become essential for developing groundbreaking treatments.
​
KEY TAKEAWAYS
-
Understand the diverse landscape of new drug modalities and their transformative potential
-
Learn strategic approaches for navigating the risks and opportunities in multimodal drug discovery
-
Discover the importance of collaborative ecosystems and data-driven strategies in driving innovation
-
Explore how Revvity Signals' solutions can support and accelerate multimodal drug discovery efforts
​
Peptide Drug Hunting: Innovative Science & Technology Empowering Breakthrough Medicines​​
New Synthetic Modalities for Target Validation
High-Content Imaging to identify small molecule modulators against Protein-Protein & RNA-Protein interactions​​
​
Iktos is a cutting-edge drug discovery company dedicated to transforming molecular discovery. Our unique platform is built on three key pillars: generative design, automated synthesis, and innovative biology. We’ll highlight our advanced screening technology, which excels at targeting challenging systems such as protein-protein interactions, RNA-protein interactions, and protein aggregation.​
​
Unlocking the Potential of Model-Informed Drug Development for mRNA Therapeutics and Vaccines​​
​
The role of pharmacometrics or modeling and simulation in the development of mRNA therapeutics and mRNA vaccines will be presented.
The talk will include the following topics:
-
Translational modeling approaches for mRNA therapeutics to guide first-in-human dose selection
-
Modeling and simulation approaches to inform Phase III dose selection for mRNA vaccines
-
Modeling and simulation to guide dose selection for mRNA pediatric vaccines​
Sponsors
